Bellerophon Provides Clinical Program Update and Reports Third Quarter 2022 Financial Results

2022-11-14

临床2期财报临床结果临床3期

WARREN, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the third quarter ended September 30, 2022. “We continue to achieve important progress in advancing the ongoing REBUILD Phase 3 trial of INOpulse® for the treatment of fibrotic Interstitial Lung Disease (fILD),” said Naseem Amin, M.D., Chairman of Bellerophon’s Board of Directors. “With the recent U.S. Food and Drug Administration (FDA) acceptance of the reduction in the study sample size, we are well positioned to accelerate the completion of the REBUILD study, which is now approximately 85% enrolled. We expect that enrollment will conclude in the first quarter of 2023, with the reporting of pivotal top-line data in third quarter of 2023,” said Peter Fernandes, Bellerophon’s Principal Executive Officer. Clinical Program Highlights: Fibrotic Interstitial Lung Disease (fILD) REBUILD Phase 3 Study: Phase 3 REBUILD registrational study enrollment of INOpulse for the treatment of fILD is approaching completion. The reduced study size is 140 fILD patients who will be treated with either INOpulse at a dose of iNO45 or a placebo. The new study size does not impact the trial’s principal objective or endpoints and maintains power of >90% (p-value < 0.01) for the primary endpoint of Moderate to Vigorous Physical Activity (MVPA) based on the effect size observed in Phase 2. If approved, INOpulse would become the first therapy to treat a broad fILD population that includes patients at low-, intermediate- and high-risk of pulmonary hypertension. Following the evaluation of baseline MVPA characteristics, as measured by actigraphy, compliance to treatment, and review of safety data of randomized subjects in the ongoing Phase 3 REBUILD study, the trial’s independent Data Monitoring Committee (DMC) supported reducing the target study size from 300 to 140 subjects. The Phase 3 program builds on positive top-line results from the Company’s previously reported Phase 2 studies for INOpulse for the treatment of fILD which showed benefits in multiple cardiopulmonary parameters, including pulmonary vascular resistance and improvement in MVPA. Pulmonary Hypertension-Sarcoidosis (PH-Sarc) Phase 2 Clinical Study: In December 2021, Bellerophon reported positive top-line data from the completed Phase 2 dose escalation study of INOpulse evaluating the acute hemodynamic benefit of INOpulse via right heart catheterization for the treatment of pulmonary hypertension associated with sarcoidosis (PH-Sarc). PH-Sarc is an unmet medical need with no approved therapies and a median survival of approximately five years after diagnosis. The Phase 2 trial was designed as a proof-of-concept study to determine if iNO could demonstrate hemodynamic benefit in PH-Sarc. All eight subjects demonstrated decreases in mean pulmonary arterial pressure (mPAP) and pulmonary vascular resistance (PVR) across the doses of INOpulse utilized in the study. The dose of iNO45 (45 mcg/kg IBW/hr) resulted in a median drop of 20% (-54% to +22%) in PVR, compared to a median baseline PVR of 329 dyne/cm.sec-5; a reduction of 20% or more in PVR is generally considered to be clinically meaningful. Along with the improvements in PVR, mPAP decreased by a median of 6-10% across the doses of iNO30 to iNO125, compared to a median baseline mPAP of 37.2 mmHg. No treatment-emergent adverse events (TEAEs) or serious adverse events (TESAEs) occurred during the acute hemodynamic dose escalation phase of the study. Based on the results of the acute dose escalation study, Bellerophon designed and submitted to the FDA a proposed exploratory Phase 2 double-blinded placebo-controlled study to investigate the safety and efficacy of iNO45 dosed chronically for six months in patients with PH-Sarc. Subsequently, the Company received FDA clearance to conduct the study and the Company is currently assessing the next steps for the study. Third Quarter Ended September 30, 2022, Financial Results: For the three months ended September 30, 2022, the Company reported a net loss of $5.1 million, or $(0.53) per basic and diluted share, compared to a net loss of $4.6 million, or $(0.49) per basic and diluted share, for the three months ended September 30, 2021. Research and development expenses for the three months ended September 30, 2022, were $3.8 million, compared to $ 3.0 million in the prior year period. The increase was primarily due to the ongoing Phase 3 fILD trial. General and administrative expenses for the three months ended September 30, 2022, were $1.4 million, as compared to $1.8 million in the prior year period. The decrease was primarily due to due to fewer labor, and stock-based compensation costs. Nine Months Ended September 30, 2022, Financial Results: For the nine months ended September 30, 2022, the Company reported a net loss of $14.8 million, or $(1.55) per basic and diluted share, compared to a net loss of $13.5 million, or $(1.42) per basic and diluted share, in the nine months ended September 30, 2021. Research and development expenses for the nine months ended September 30, 2022 were $12.6 million, compared to $9.9 million in the prior year period. The increase was primarily due to the ongoing Phase 3 fILD trial. General and administrative expenses for the nine months ended September 30, 2022 were $4.7 million, compared to $6.0 million in the prior year period. The decrease was primarily due to lower consulting, labor, and stock-based compensation costs. Balance Sheet As of September 30, 2022, the Company had unrestricted cash and cash equivalents of $11.3 million, compared to unrestricted cash and cash equivalents of $24.7 million on December 31, 2021. About Bellerophon Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit Forward-looking Statements Any statements in this press release about Bellerophon’s future expectations, plans, and prospects, including statements about the clinical development of its product candidates, regulatory actions with respect to the Company’s clinical trials and expectations regarding the sufficiency of the Company’s cash balance to fund clinical trials, operating expenses and capital expenditures, and other statements containing the words “anticipate,” “believe,” “continue,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks and uncertainties relating to INOpulse®, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary or interim results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, the FDA’s substantial discretion in the approval process, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K and in subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent Bellerophon’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release. Contacts LifeSci Advisors: Brian Ritchie (212) 915-2578 britchie@lifesciadvisors.com BELLEROPHON THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands except share and per share data) As of As of September 30, 2022 December 31, 2021 (Unaudited) Assets Current assets: Cash and cash equivalents $ 11,317 $ 24,736 Restricted cash 404 103 Prepaid expenses and other current assets 338 620 Total current assets 12,059 25,459 Restricted cash, non-current — 300 Right of use assets, net 357 863 Property and equipment, net 6 67 Other non-current assets 186 186 Total assets $ 12,608 $ 26,875 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 1,525 $ 1,192 Accrued research and development 1,888 1,397 Accrued expenses 1,370 1,711 Current portion of operating lease liabilities 396 752 Total current liabilities 5,179 5,052 Long term operating lease liabilities — 203 Common stock warrant liability 1 1 Total liabilities 5,180 5,256 Commitments and contingencies Stockholders' equity: Common stock, $0.01 par value per share; 200,000,000 shares authorized and 9,545,451 and 9,545,451 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively 95 95 Preferred stock, $0.01 par value per share; 5,000,000 shares authorized, zero shares issued and outstanding at September 30, 2022 and December 31, 2021 — — Additional paid-in capital 254,395 253,771 Accumulated deficit (247,062 ) (232,247 ) Total stockholders' equity 7,428 21,619 Total liabilities and stockholders' equity $ 12,608 $ 26,875 BELLEROPHON THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) (in thousands except share and per share data) Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Operating expenses: Research and development $ 3,750 $ 3,030 $ 12,646 $ 9,853 General and administrative 1,366 1,773 4,653 6,035 Total operating expenses 5,116 4,803 17,299 15,888 Loss from operations (5,116 ) (4,803 ) (17,299 ) (15,888 ) Change in fair value of common stock warrant liability — 167 — 600 Interest and other income, net 47 2 67 4 Pre-tax loss (5,069 ) (4,634 ) (17,232 ) (15,284 ) Income tax benefit — — 2,417 1,800 Net loss and comprehensive loss $ (5,069 ) $ (4,634 ) $ (14,815 ) $ (13,484 ) Weighted average shares outstanding: Basic 9,545,451 9,506,419 9,545,451 9,501,428 Diluted 9,545,451 9,506,419 9,545,451 9,501,428 Net loss per share: Basic $ (0.53 ) $ (0.49 ) $ (1.55 ) $ (1.42 ) Diluted $ (0.53 ) $ (0.49 ) $ (1.55 ) $ (1.42 )